Sign In
Buy ALDX
$1.54
-0.0600 (-3.75%)
At Close: Jul 31, 2026
Aldeyra to Participate in the American Academy of Ophthalmology Eyecelerator 2020 Virtual Conference on Friday, November 6
08:00am, Wednesday, 04'th Nov 2020
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., will discuss Aldeyra's novel therapeutic appro
Aldeyra Has 'Catalayst-Rich' 12 Months Ahead, Jefferies Says In Bullish Initiation
09:22pm, Friday, 30'th Oct 2020
Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a company focusing on immune-mediated diseases, are primed for further upside, according to a Jefferies analyst. The Aldeyra Analyst: Kelly Shi ini
Aldeyra Therapeutics: A New Cure To A Serious 21st Century Problem
01:27pm, Wednesday, 02'nd Sep 2020
Allergy is a serious rising threat to the new urban lifestyle. Aldeyra’s drug might have the right answer to this problem.
Week 35 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
06:23am, Monday, 24'th Aug 2020
Two Sample Breakout Stocks for Week 35 with better than 10% short-term upside potential. Now up an average 172.2% YTD.
Aldeyra Therapeutics, Inc. (ALDX) Upgraded to Buy: Here's What You Should Know
04:00pm, Wednesday, 12'th Aug 2020
Aldeyra Therapeutics, Inc. (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Aldeyra's (ALDX) Q2 Earnings Beat Estimates, Pipeline in Focus
02:09pm, Thursday, 06'th Aug 2020
Aldeyra (ALDX) reports narrower-than-expected loss in the second quarter of 2020.
Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update
11:00am, Thursday, 06'th Aug 2020
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immun
Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing?
02:07pm, Tuesday, 04'th Aug 2020
Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
12:00pm, Tuesday, 04'th Aug 2020
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting 1x1 meetings at the following virtual investor conferences in August:
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Expected to Post Earnings of -$0.34 Per Share
06:18am, Tuesday, 04'th Aug 2020
Equities research analysts expect Aldeyra Therapeutics, Inc (NASDAQ:ALDX) to post earnings of ($0.34) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Aldeyra Th
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Down 8.7% in July
03:46am, Tuesday, 04'th Aug 2020
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) saw a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 574,100 shares, a decrease of 8.7% from t
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
12:00am, Tuesday, 04'th Aug 2020
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting 1x1 meetings at the followin
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second-Quarter 2020 Financial Results and Corporate Update
12:00pm, Thursday, 30'th Jul 2020
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immun
Two Sigma Advisers LP Boosts Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)
11:26pm, Wednesday, 15'th Jul 2020
Two Sigma Advisers LP lifted its stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 239.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange
Aldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity Partners
12:00pm, Tuesday, 14'th Jul 2020
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today a
